Please provide your email address to receive an email when new articles are posted on . Switching from a TNF inhibitor to upadacitinib was superior to cycling TNF inhibitors. Upadacitinib outcomes ...
Tumor necrosis factor (TNF) inhibitor use was associated with a lower risk of cardiovascular outcomes in patients with radiographic axial spondyloarthritis in a recent study. Axial spondyloarthritis ...
Please provide your email address to receive an email when new articles are posted on . SCOTTSDALE, Ariz. — Interleukin-17 targeting, a tyrosine kinase 2 inhibitor and the “nanobody revolution” ...
Guselkumab 100 mg, administered every 4 or 8 weeks, led to significant improvements in signs and symptoms of active psoriatic arthritis (PsA) in patients with inadequate response to only one prior TNF ...
Today, AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating ...
Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors was paradoxically associated with an increased risk for other immune-mediated inflammatory diseases (IMIDs) in a ...
Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed to reach the primary endpoint in a Phase II trial. Preliminary results ...
Anti-tumor necrosis factor (TNF) therapy for new-onset inflammatory bowel disease (IBD) was independently associated with progressive kidney function decline but not survival, a VA cohort study found.
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results